Elutia Inc (ELUT)
ELUT Stock Price Chart
Explore Elutia Inc interactive price chart. Choose custom timeframes to analyze ELUT price movements and trends.
ELUT Company Profile
Discover essential business fundamentals and corporate details for Elutia Inc (ELUT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Oct 2020
Employees
26.00
Website
https://elutia.comCEO
C. Randal Mills
Description
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
ELUT Financial Timeline
Browse a chronological timeline of Elutia Inc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 14 Aug 2026
EPS estimate is -$0.15, while revenue estimate is $2.90m.
Earnings released on 14 May 2026
EPS came in at -$0.17 falling short of the estimated -$0.15 by -13.33%, while revenue for the quarter reached $3.11m , beating expectations by +3.80%.
Earnings released on 11 Mar 2026
EPS came in at -$0.14 matching the estimated -$0.14, while revenue for the quarter reached $3.27m , missing expectations by -0.88%.
Earnings released on 6 Nov 2025
EPS came in at -$0.01 surpassing the estimated -$0.16 by +93.55%, while revenue for the quarter reached $3.32m , beating expectations by +0.70%.
Earnings released on 14 Aug 2025
EPS came in at -$0.26 falling short of the estimated -$0.17 by -52.94%, while revenue for the quarter reached $6.26m , missing expectations by -15.36%.
Earnings released on 8 May 2025
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%, while revenue for the quarter reached $6.03m , missing expectations by -9.32%.
Earnings released on 6 Mar 2025
EPS came in at -$0.26 falling short of the estimated -$0.25 by -4.00%, while revenue for the quarter reached $5.47m , missing expectations by -7.32%.
Earnings released on 14 Nov 2024
EPS came in at -$0.33 surpassing the estimated -$0.44 by +25.00%, while revenue for the quarter reached $5.92m , missing expectations by -7.47%.
Earnings released on 7 Aug 2024
EPS came in at -$1.14 falling short of the estimated -$0.33 by -245.45%, while revenue for the quarter reached $6.29m , missing expectations by -5.40%.
Earnings released on 9 May 2024
EPS came in at -$0.75 falling short of the estimated -$0.41 by -82.93%, while revenue for the quarter reached $6.69m , beating expectations by +9.74%.
Earnings released on 7 Mar 2024
EPS came in at -$0.66 falling short of the estimated -$0.28 by -135.71%, while revenue for the quarter reached $5.88m , missing expectations by -10.31%.
Earnings released on 13 Nov 2023
EPS came in at -$0.50 surpassing the estimated -$0.53 by +5.66%, while revenue for the quarter reached $6.13m , missing expectations by -16.07%.
Earnings released on 14 Aug 2023
EPS came in at -$0.65 falling short of the estimated -$0.29 by -124.14%, while revenue for the quarter reached $10.30m , missing expectations by -17.63%.
Earnings released on 10 May 2023
EPS came in at -$0.49 surpassing the estimated -$0.54 by +9.26%, while revenue for the quarter reached $13.05m , missing expectations by -4.74%.
Earnings released on 22 Mar 2023
EPS came in at -$0.38 surpassing the estimated -$0.69 by +44.93%, while revenue for the quarter reached $12.67m , beating expectations by +0.92%.
Earnings released on 14 Nov 2022
EPS came in at -$0.73 falling short of the estimated -$0.67 by -9.77%, while revenue for the quarter reached $12.39m , beating expectations by +0.09%.
Earnings released on 11 Aug 2022
EPS came in at -$0.69 falling short of the estimated -$0.56 by -23.77%, while revenue for the quarter reached $12.64m , beating expectations by +9.09%.
ELUT Stock Performance
Access detailed ELUT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
